Merck KGaA signs DNA damage response cancer deal with Artios PharmaGermany’s Merck KGaA has joined with UK-based Artios Pharma in a potential multi-billion dollar deal to investigate novel Share XMerck KGaA signs DNA damage response cancer deal with Artios Pharmahttps://pharmaphorum.com/news/merck-kgaa-signs-dna-damage-response-cancer-deal-with-artios-pharma/
Scotland backs Merck/Pfizer’s Bavencio combo for kidney cancerThe Scottish Medicines Consortium (SMC) backed NHS use of nine new medicines at its meeting this week, including Share XScotland backs Merck/Pfizer’s Bavencio combo for kidney cancerhttps://pharmaphorum.com/news/scotland-backs-merck-pfizers-bavencio-combo-for-kidney-cancer/
FDA starts quick review of Merck’s MET-targeting lung cancer drugMerck KGaA could be looking at an early 2021 approval for its MET inhibitor tepotinib in lung cancer Share XFDA starts quick review of Merck’s MET-targeting lung cancer drughttps://pharmaphorum.com/news/fda-starts-quick-review-of-mercks-met-targeting-lung-cancer-drug/
NICE backs kidney cancer combination from Merck KGaA and PfizerNICE has said a combination of Merck KGaA’s Bavencio and Pfizer’s Inlyta should be available as a first Share XNICE backs kidney cancer combination from Merck KGaA and Pfizerhttps://pharmaphorum.com/news/nice-backs-kidney-cancer-combination-from-merck-kgaa-and-pfizer/
Merck KGaA takes second option from cancer immunotherapy pact with F-StarGermany’s Merck KGaA has taken an option on a second cancer immunotherapy drug from its development deal with Anglo-American biotech F-star Therapeutics. The companies Share XMerck KGaA takes second option from cancer immunotherapy pact with F-Starhttps://pharmaphorum.com/news/merck-kgaa-takes-second-option-from-cancer-immunotherapy-pact-with-f-star/
Merck KGaA’s ATR cancer drug cleared for further trials after phase 1 trial successMerck KGaA’s ATR inhibitor cancer drug has been cleared for further clinical trials after it showed encouraging activity in Share XMerck KGaA’s ATR cancer drug cleared for further trials after phase 1 trial successhttps://pharmaphorum.com/news/mercks-atr-cancer-drug-cleared-for-clinical-trials-after-phase-1-trial-success/
Merck & Co’s Keytruda outperforms chemo in MSI-High colorectal cancerMerck & Co’s Keytruda (pembrolizumab) immunotherapy has outperformed standard of care in untreated colorectal cancer with certain mutations, Share XMerck & Co’s Keytruda outperforms chemo in MSI-High colorectal cancerhttps://pharmaphorum.com/news/merck-cos-keytruda-outperforms-chemo-in-msi-high-colorectal-cancer/
FDA approves Pfizer/Merck KGaA combo in advanced colorectal cancerThe FDA has approved a combination of Pfizer’s Braftovi and Merck KGaA’s Erbitux for a form of untreated Share XFDA approves Pfizer/Merck KGaA combo in advanced colorectal cancerhttps://pharmaphorum.com/news/fda-approves-pfizer-merck-kgaa-combo-in-advanced-colorectal-cancer/
BI opens second branch of digital lab in ChinaBoehringer Ingelheim has announced that it will open a second branch of its digital lab, BI X, in Share XBI opens second branch of digital lab in Chinahttps://pharmaphorum.com/news/bi-opens-branch-of-digital-lab-in-china/
